RxDoctor Payments DataLook up a doctor →

Justin Greiwe, MD

Allergy & Immunology · Cincinnati, OHNPI 1942444807

Payments from drug & device makers

$1,044,391in general payments, 2019–2025

Across 1,966 payments — averaging $531.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$509K
  • Sanofi$227K
  • Regeneron Healthcare Solutions, Inc.$82K
  • AbbVie$53K
  • Genentech USA, Inc.$52K
  • Dermavant Sciences, Inc.$32K
  • plus $89K from 47 others

What the payments were for

  • Consulting fees$216,24521%
  • Speaking & faculty fees$706,30268%
  • Grants$3,0000%
  • Travel & lodging$73,2367%
  • Food & beverage$45,3414%
  • Education$2680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,044,391 in reported general payments places this provider in the 95th percentile of 128 allergy & immunology providers in Ohio.

See all allergy & immunology providers in Ohio

Medicare billing

Part B allowed, 2024
$19,173
Medicare patients
110
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab23$93,608
TezspireTezepelumab-Ekko12$49,150
Dupixent SyringeDupilumab11$40,128
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$32,059
Spiriva RespimatTiotropium Bromide36$19,660
Breo ElliptaFluticasone/Vilanterol36$15,189
Arnuity ElliptaFluticasone Furoate28$8,518
AlvescoCiclesonide18$8,092
Advair HfaFluticasone Propion/Salmeterol12$5,787
SymbicortBudesonide/Formoterol Fumarate23$5,254
Qvar RedihalerBeclomethasone Dipropionate12$4,860
SingulairMontelukast Sodium13$3,323
Azelastine Hcl113$2,656
Cyclosporine ModifiedCyclosporine, Modified15$1,745
Azelastine-FluticasoneAzelastine/Fluticasone14$1,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$11,159$55,765102 claims
AstraZenecaTezspire, Symbicort$509,190$54,40435 claims
Boehringer IngelheimSpiriva Respimat$107$19,66036 claims
Covis Pharma GmbHAlvesco$556$8,09218 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$292$4,86012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 128 allergy & immunology providers in Ohio.

Other allergy & immunology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →